Unsafe and unregulated cell therapies being sold in Europe
The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...
Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion
Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
The Pharma Letter7h
EMA annual report 2024
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...
MIT Technology Review9h
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...